|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Current assets: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Short-term investments | ||||||||||||||||||||
| Accounts receivable | ||||||||||||||||||||
| Inventory, net | ||||||||||||||||||||
| Other current assets (including $0 and $429 as of June 30, 2026 and December 31, 2025, respectively, from a related party) | ||||||||||||||||||||
| Assets held for sale | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Long-term investments | ||||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||||
| Operating lease right-of-use assets | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Equity method investment in Gannet BioChem | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) | ||||||||||||||||||||
| Current liabilities: | ||||||||||||||||||||
| Accounts payable (including $456 and $137 as of June 30, 2026 and December 31, 2025, respectively, to a related party) | ||||||||||||||||||||
| Accrued compensation | ||||||||||||||||||||
| Accrued clinical trial expenses | ||||||||||||||||||||
| Other accrued expenses | ||||||||||||||||||||
| Accrued expenses (including $130 and $994 as of June 30, 2026 and December 31, 2025, respectively, to a related party) | ||||||||||||||||||||
| Operating lease liabilities, current portion | ||||||||||||||||||||
| Liabilities related to assets held for sale | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Operating lease liabilities, less current portion | ||||||||||||||||||||
| Liabilities related to the sales of future royalties, net | ||||||||||||||||||||
| Other long-term liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Stockholders' equity: | ||||||||||||||||||||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares designated or outstanding at June 30, 2026 or December 31, 2025, respectively | ||||||||||||||||||||
| Common stock, $0.0001 par value; 390,000,000 shares authorized; 34,129,664 shares and 20,378,832 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively | ||||||||||||||||||||
| Capital in excess of par value | ||||||||||||||||||||
| Treasury stock, at cost; no shares as of March 31, 2026 or December 31, 2025, respectively | ||||||||||||||||||||
| Accumulated other comprehensive income (loss) | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total stockholders' equity | ||||||||||||||||||||
| Total liabilities and stockholders' equity | ||||||||||||||||||||
Loading...
